Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design

Gallo, 2006, Adaptive designs in clinical drug development – an Executive Summary of the PhRMA Working Group, J Biopharm Stat, 16, 275, 10.1080/10543400600614742

Chow, 2008, Adaptive design methods in clinical trials – a review, Orphanet J Rare Dis, 3, 10.1186/1750-1172-3-11

Bauwens, 2009, 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol, Curr Med Res Opin, 25, 463, 10.1185/03007990802675096

Rennard, 2008, A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison, Respir Med, 102, 1033, 10.1016/j.rmed.2008.02.001

Beier, 2007, Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial, Pulm Pharmacol Ther, 20, 740, 10.1016/j.pupt.2006.09.001

Fogarty, 2009, Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium, Eur Respir J, 34

Chung, 2009, Safety and tolerability of indacaterol over 52 weeks of treatment in COPD, Am J Respir Crit Care Med, 179

Barr, 2005, Inhaled tiotropium for stable chronic obstructive pulmonary disease, Cochrane Database Syst Rev, 2, 10.1002/14651858.CD002876.pub2

Barr, 2006, Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis, Thorax, 61, 854, 10.1136/thx.2006.063271

Dahl, 2001, Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 164, 778, 10.1164/ajrccm.164.5.2007006

Rossi, 2002, Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD, Chest, 121, 1058, 10.1378/chest.121.4.1058

Richter, 2006, Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD, Respiration, 73, 414, 10.1159/000091996

Cazzola, 2008, Outcomes for COPD pharmacological trials: from lung function to biomarkers, Eur Respir J, 31, 416, 10.1183/09031936.00099306

Donohue, 2005, Minimal clinically important differences in COPD lung function, COPD, 2, 111, 10.1081/COPD-200053377

Cerveri, 2000, Mechanisms for isolated volume response to a bronchodilator in patients with COPD, J Appl Physiol, 88, 1989, 10.1152/jappl.2000.88.6.1989

O'Donnell, 2001, Evaluation of bronchodilator responses in patients with ‘irreversible’ emphysema, Eur Respir J, 18, 914, 10.1183/09031936.01.00216501

Newton, 2002, Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation, Chest, 121, 1042, 10.1378/chest.121.4.1042

Dahl, 2009, Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol, Eur Respir J, 34, E4350

U.S. Department of Health and Human Services Food and Drug Administration

U.S. Department of Health and Human Services Food and Drug Administration

Krams, 2007, Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop, J Biopharm Stat, 17, 957, 10.1080/10543400701643764